ホーム › びまん性大細胞型B細胞リンパ腫 › カリフォルニア州
カリフォルニア州におけるびまん性大細胞型B細胞リンパ腫の臨床試験
カリフォルニア州内の拠点で、びまん性大細胞型B細胞リンパ腫に関する42件の研究が参加者を募集しています。
カリフォルニア州内の都市
- Baldwin Park19件の研究
- Los Angeles17件の研究
- Sacramento8件の研究
- San Francisco8件の研究
- San Diego5件の研究
- Mountain View4件の研究
- Orange3件の研究
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0135), Burbank
- City of Hope Comprehensive Cancer Center ( Site 0191), Duarte
- Bass Medical Group ( Site 0123), Walnut Creek
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Bass Medical Group ( Site 0166), Walnut Creek
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05139017A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- David Geffen School of Medicine at UCLA, Los Angeles
- University of California Irvine Medical Center, Orange
- UC Davis Comprehensive Cancer Center, Sacramento
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Providence Medical Foundation-Oncology ( Site 0168), Fullerton
- MemorialCare Health System - Long Beach Medical Center ( Site 9559), Long Beach
- Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- City of Hope, Duarte
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
- University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- City of Hope Medical Center, Duarte
- University of California San Diego Medical Center, Moores Cancer Center, La Jolla
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Community Cancer Institute (CCI), Clovis
- Providence Medical Foundation, Fullerton
- Los Angeles Cancer Network, Glendale
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT05272384Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Alta Bates Summit Medical Center, Berkeley
- City of Hope, Duarte
- Cedars-Sinai Medical Center, Los Angeles
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07365306A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第1相
18歳〜85歳 · 全性別 · 2026/08/10更新 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Stanford University, Stanford
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/05更新 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA), Los Angeles
- University of California, Irvine, Orange
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07424833Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/17更新 · NCT05052528DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05672251Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- City of Hope Comprehensive Cancer Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05077527Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT06015880Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/08更新 · NCT06854159A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/30更新 · NCT06905509Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/22更新 · NCT04545762Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/20更新 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- 他1件
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
- University of California Davis Comprehensive Cancer Center, Sacramento
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/03/10更新 · NCT05256641Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
- City of Hope Medical Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/05更新 · NCT07042438Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/23更新 · NCT05432635Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/02/04更新 · NCT05800405Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- UC Irvine Health Cancer Center-Newport, Costa Mesa
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UCI Health Laguna Hills, Laguna Hills
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Tower Cancer Research Foundation, Beverly Hills
- City of Hope Comprehensive Cancer Center, Duarte
- City of Hope Seacliff, Huntington Beach
- 他7件
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352A Study of NX-1607 in Adults With Advanced Malignancies
- University of Southern California, Los Angeles
- University of California, San Francisco, San Francisco
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。